CoBRE for Signal Transduction and Cancer Phase III

我们的长期目标是为西弗吉尼亚州和周围的阿巴拉契亚地区建立一个NCI指定的癌症中心。西弗吉尼亚大学(WVU)是该州的旗舰大学和医疗中心，目前西弗吉尼亚没有癌症中心被指定为NCI。我们的L-11期信号转导与癌症中心(P20)旨在支持基础研究发展，将其作为成功竞争癌症中心支持拨款和西弗吉尼亚大学玛丽·巴巴伦道夫癌症中心NCI称号的关键组成部分。我们第一阶段和第二阶段眼镜蛇的具体目标从最初专注于初级调查人员，主要目标是促进职业发展和独立资助(第一阶段)，演变为继续支持初级调查人员，并在第二阶段期间在目标主题领域建立临界质量。此外，在L-第二阶段期间，支持建立和加强必要的核心设施，这一关键核心和基础设施支持的最后阶段确定了我们第三阶段(P30)过渡奖的重点。 MBRCC已确立的科学主题领域包括侧重于EMT和转移的分子机制、乳腺癌、恶性造血疾病和移植，以及转基因烟草减少研究的项目。这些计划为MBRCC成员提供了一个有组织的合作和指导的氛围，并提供了一个平台，在这个平台上形成了多名研究人员和方案赠款申请。与这一过渡奖申请相关的是，所有这些计划中的项目都得到了需要支持的核心的支持：流式细胞术、显微镜成像、动物模型和成像、蛋白质、生物统计学和生物信息学以及生物谱学处理。这一第三阶段过渡奖的具体目标包括(1)支持先进的技术和可持续核心设施方面的专业知识，强调可获得性和培训，在其中我们培养从事癌症相关研究的研究人员的职业发展；(2)加强与MBRCC、西弗吉尼亚大学和国家的合作，以最大限度地发挥Cobre投资的影响，以确保最大限度地获得高质量、外部资助的研究所需的技术。重点放在支持合作、可持续性和避免重复投资的战略上，以产生该奖项对MBRCC持续增长的最大影响，部分原因是通过提供突出的核心设施支持。总而言之，这些努力支持我们指定NCI的长期目标。

Our long term goal is to establish an NCI designated cancer center for West Virginia (WV) and the surrounding Appalachian region. West Virginia University (WVU) is the flagship university and medical center in the state with no cancer centers in WV currently having NCI designation. Our Phase l-ll CoBREs for Signal Transduction and Cancer (P20) were designed to support basic research development as a critical component of successfully competing for a Cancer Center Support Grant (CCSG) and coincident NCI designation for the WVU Mary Babb Randolph Cancer Center (MBRCC). The specific aims of our Phase I and Phase II CoBREs evolved from an initial focus on junior investigators with a primary goal of nurturing career development and independent funding (Phase I) to a combination of continued support of junior investigators with establishment of a critical mass in targeted thematic areas during Phase II. In addition, the establishment and strengthening of essential core facilities was supported during Phases l-ll and the final stage of this critical core and infrastructure support defines the focus of our Phase III (P30) Transition Award. Established scientific thematic areas in the MBRCC include Programs focused on the Molecular Mechanisms of EMT and Metastasis, Breast Cancer, Hematopoietic Malignancies and Transplantation, and Translational Tobacco Reduction Research. These Programs provide a structured atmosphere for collaboration and mentoring for the MBRCC members and the platform in which to shape multi-investigator and programmatic grant applications. Relevant to this Transition Award application, projects throughout all of these Programs are supported by the Cores for which support is requested: Flow Cytometry, Microscope Imaging, Animal Models and Imaging, Protein, Biostatistics and Bioinformatics, and Biospecimen Processing. The specific aims of this Phase III Transition Award include (1) support of state-of-the-art technology and expertise in sustainable core facilities that emphasize accessibility and training in which we nurture career development of investigators undertaking cancer related research and (2) enhanced collaboration in the MBRCC, WVU and the state to maximize the impact of CoBRE investment to ensure maximum access to technology required for high quality, extramurally funded research. Emphasis has been placed on strategies to support collaboration, sustainability, and an avoidance of redundant investment to yield the greatest impact of this award on continued growth of the MBRCC, in part, through availability of outstanding core facility support. Collectively, these efforts support our long-term goal of NCI designation.